Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Now Available: Pipeline and Commercial Insight: Pneumococcal and Meningococcal VaccinesNew Pharmaceuticals market report from Datamonitor: "Pipeline and Commercial Insight: Pneumococcal and Meningococcal Vaccines"
Features and benefits In-depth analysis of market dynamics for pneumo-and meningococcal vaccines across US, 5EU and Japan, supported by insights of key opinion leaders Population-based 10-year sales forecasts for currently available brands and late-stage pipeline vaccines in the US and 5EU. Epidemiology section discussing key population trends and epidemiological features of pneumo- and meningococcal disease in the seven major markets Thorough assessments of key marketed vaccines and late stage pipeline products. Highlights Datamonitor anticipates the launch of Pfizer's Prevnar 13 for adults in 2011 and expects the vaccine to quickly replace Merck & Co's Pneumovax 23 as the gold standard for the primary immunization of elderly and high-risk adults, driving Prevnar 13 to annual sales of $3.4 billion in 2019 across the US and five major EU markets. Sales expectations for conjugate MenACWY vaccines are limited in the seven major markets. While the US are unlikely to recommend routine MenACWY vaccination of infants, MenACWY vaccines will continue to play only a marginal role in Europe, unless a marked serogroup shift occurs. Best growth opportunities lie in a meningococcal B vaccine. Pneumo- and meningococcal vaccines continue to offer great commercial opportunities due to changing disease epidemiology and extension of age indications. Novartis' 4CMenB is the most promising pipeline vaccine and expected to quickly reach blockbuster status with possible sales of almost $3 billion in the US and the five major European ma Your key questions answered Identify the market dynamics of pneumo- and meningococcal vaccines, success factors for leading brands and the potential of late stage pipeline Obtain full country and product-specific forecasts of currently marketed and pipeline pneumo- and meningococcal vaccines from 2010 to 2019. Understand epidemiological trends of pneumo-and meningococcal disease across the seven major markets and their impact on vaccination recommendations For more information or to purchase this report, go to: - http://www.fastmr.com/ Partial Table of Contents: TABLE OF CONTENTS OVERVIEW 1 Catalyst 1 Summary 1 About Datamonitor healthcare 2 About the Vaccines & Infectious Diseases Pharmaceutical Analysis Team 2 EXECUTIVE SUMMARY 3 Strategic scoping and focus 3 Datamonitor insight into the pneumococcal and meningococcal vaccines market 3 Related reports 4 Upcoming related reports 4 PNEUMOCOCCAL VACCINES 19 Summary 19 Pneumococcal disease background 20 Epidemiological context 21 Introduction 21 Key points 21 Disease definition and diagnosis criteria 21 Surveillance of invasive pneumococcal disease 22 Impact of vaccines 23 Serotype replacement 23 Market-specific epidemiology 25 US 30 Japan 31 France 31 Germany 32 Italy 32 Spain 33 UK 34 Epidemiologic forecasting of IPD vaccine-eligible population 35 US 36 France 38 Germany 38 Italy 38 Spain 38 UK 38 Results 39 Discussion 42 Vaccination recommendations 42 Infants 43 Launch of first conjugate vaccine Prevnar 7 from 2000 onwards allowed routine vaccination of infants 43 Prevnar 13 is set to entirely replace Prevnar 7 in infants 43 US 45 Japan 46 France 46 Germany 47 Italy 47 Spain 49 UK 50 Adults and elderly 50 Prevnar 13 is likely to replace Pneumovax 23 in primary vaccination of adults and elderly 50 US 52 Japan 53 France 53 Germany 53 Italy 53 Spain 53 UK 53 Vaccination coverage 54 Infants 54 US 55 Japan 56 France 56 Germany 57 Italy 57 Spain 58 UK 58 Adults and elderly 58 US 58 Japan 60 France 60 Germany 61 Italy 61 Spain 61 UK 61 Overview of the competitive landscape 63 Four vaccines are marketed for the prevention of infection with S. pneumoniae 63 There are different strategies to boost the primary immune response of conjugate vaccines 64 Key companies and strategies 66 Pfizer - clear dominance through Prevnar franchise 67 Merck & Co - increasing pressure for Pneumovax 68 GlaxoSmithKline - emerging markets as an expansion strategy for Synflorix 68 Deals with GAVI provide an opportunity to penetrate developing markets 69 Access to potential future markets is a key incentive for pharmaceutical companies 72 WHO request for additional trials on Synflorix two-dose presentation expected to delay vaccine allocation 72 Unmet needs 73 Marketed and pipeline vaccines 74 Pneumovax (23-valent pneumococcal polysaccharide vaccine, Merck & Co) 74 Overview 74 Vaccine profile 75 Product positioning 75 SWOT analysis 77 Satisfaction of unmet needs 81 Forecast to 2019 81 Prevnar 7 (7-valent pneumococcal conjugate vaccine, Pfizer) 82 Overview 82 Vaccine profile 85 Drug positioning 85 SWOT analysis 86 Satisfaction of unmet needs 89 Forecast to 2019 90 Prevnar 13 (13-valent pneumococcal conjugate vaccine, Pfizer) 90 Overview 90 Vaccine profile 92 Clinical trial data 92 Drug positioning 103 SWOT analysis 103 Satisfaction of unmet needs 108 Forecast to 2019 108 Synflorix (10-valent pneumococcal conjugate vaccine, GlaxoSmithKline) Overview 110 Vaccine profile 111 Clinical trial data 111 Full Table of Contents is available at: -- http://www.fastmr.com/ About Datamonitor The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|